PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PPAR Ligands Function as Suppressors That Target Biological Actions of HMGB1
Authors
Keywords
-
Journal
PPAR Research
Volume 2016, Issue -, Pages 1-10
Publisher
Hindawi Limited
Online
2016-08-03
DOI
10.1155/2016/2612743
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PPARγ inhibits HMGB1 expression through upregulation of miR-142-3p in vitro and in vivo
- (2016) Zhiqiang Yuan et al. CELLULAR SIGNALLING
- Antineoplastic Effects of PPAR? Agonists, with a Special Focus on Thyroid Cancer
- (2016) Silvia Martina Ferrari et al. CURRENT MEDICINAL CHEMISTRY
- Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer
- (2015) Jiheum Paek et al. ARCHIVES OF GYNECOLOGY AND OBSTETRICS
- A step ahead of PPARγ full agonists to PPARγ partial agonists: Therapeutic perspectives in the management of diabetic insulin resistance
- (2015) Sridevi Chigurupati et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review
- (2015) Xuanbin Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- PPARγ-Dependent and -Independent Inhibition of the HMGB1/TLR9 Pathway by Eicosapentaenoic Acid Attenuates Ischemic Brain Damage in Ovariectomized Rats
- (2015) Manabu Sumiyoshi et al. Journal of Stroke & Cerebrovascular Diseases
- The Role of PPARγ in Advanced Glycation End Products-Induced Inflammatory Response in Human Chondrocytes
- (2015) Chi Ma et al. PLoS One
- Relationship between high-mobility group box 1 overexpression in ovarian cancer tissue and serum: a meta-analysis
- (2015) Zengjun Li et al. OncoTargets and Therapy
- High mobility group box-1 and its clinical value in breast cancer
- (2015) Yang Shanping Sun et al. OncoTargets and Therapy
- Review of the Structural and Dynamic Mechanisms of PPARγPartial Agonism
- (2015) Alice J. Kroker et al. PPAR Research
- PPARγand the Innate Immune System Mediate the Resolution of Inflammation
- (2015) Amanda Croasdell et al. PPAR Research
- PPARγ-Dependent and -Independent Inhibition of the HMGB1/TLR9 Pathway by Eicosapentaenoic Acid Attenuates Ischemic Brain Damage in Ovariectomized Rats
- (2015) Manabu Sumiyoshi et al. Journal of Stroke & Cerebrovascular Diseases
- Peroxisome proliferator-activated receptor γ-mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer
- (2014) Anna Panza et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Activation of PPARγ attenuates LPS-induced acute lung injury by inhibition of HMGB1-RAGE levels
- (2014) Guizuo Wang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of Eicosapentaenoic Acid on the Levels of Inflammatory Markers, Cardiac Function and Long-Term Prognosis in Chronic Heart Failure Patients with Dyslipidemia
- (2014) Keiichi Kohashi et al. Journal of Atherosclerosis and Thrombosis
- Pioglitazone, a PPARγ agonist, inhibits growth and invasion of human hepatocellular carcinoma via blockade of the rage signaling
- (2014) Yuan Yang et al. MOLECULAR CARCINOGENESIS
- JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation
- (2014) B. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ligand-activated peroxisome proliferator-activated receptor-δ and -γ inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1
- (2014) J S Hwang et al. Cell Death & Disease
- HMGB1 Is Involved in the Protective Effect of the PPARαAgonist Fenofibrate against Cardiac Hypertrophy
- (2014) Zhankui Jia et al. PPAR Research
- Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation
- (2013) Matthias Schmuth et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma
- (2013) Chiharu Tabata et al. BMC CANCER
- Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure
- (2013) Akira Funayama et al. CARDIOVASCULAR RESEARCH
- HMGB1 in Cancer: Good, Bad, or Both?
- (2013) R. Kang et al. CLINICAL CANCER RESEARCH
- Anti-inflammatory Effects of ω-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-II–Dependent Hypertension
- (2013) Arzu Ulu et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Serum HMGB1 as a Diagnostic Marker for Malignant Peritoneal Mesothelioma
- (2013) Chiharu Tabata et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Advanced Glycation End Products Induce Peroxisome Proliferator-Activated Receptor γ Down-Regulation-Related Inflammatory Signals in Human Chondrocytes via Toll-Like Receptor-4 and Receptor for Advanced Glycation End Products
- (2013) Ying Ju Chen et al. PLoS One
- Fenofibrate – A Potential Systemic Treatment for Diabetic Retinopathy?
- (2012) Tien Yin Wong et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis
- (2012) A.W.S. de Souza et al. AUTOIMMUNITY REVIEWS
- Telmisartan Improves Insulin Resistance of Skeletal Muscle Through Peroxisome Proliferator-Activated Receptor- Activation
- (2012) L. Li et al. DIABETES
- Activation of Peroxisome Proliferator-Activated Receptorγby Rosiglitazone Inhibits Lipopolysaccharide-Induced Release of High Mobility Group Box 1
- (2012) Jung Seok Hwang et al. MEDIATORS OF INFLAMMATION
- Thiazolidinediones and PPARγ agonists: time for a reassessment
- (2012) Bertrand Cariou et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- PPARs and Lipid Ligands in Inflammation and Metabolism
- (2011) Gregory S. Harmon et al. CHEMICAL REVIEWS
- HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammation
- (2011) José Augusto Nogueira-Machado et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Peroxisome Proliferator-Activated Receptor γ Agonist Troglitazone Inhibits High Mobility Group Box 1 Expression in Endothelial Cells Via Suppressing Transcriptional Activity of Nuclear Factor κB and Activator Protein 1
- (2011) Min Gao et al. SHOCK
- HMGB1 and RAGE in Inflammation and Cancer
- (2010) Gary P. Sims et al. Annual Review of Immunology
- Macrophages, Inflammation, and Insulin Resistance
- (2010) Jerrold M. Olefsky et al. Annual Review of Physiology
- High-mobility group box 1 and cancer
- (2010) Daolin Tang et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth
- (2010) Naohiko Hamaguchi et al. CANCER SCIENCE
- Peroxisome proliferator-activated receptor gamma in osteoarthritis
- (2010) Hassan Fahmi et al. Modern Rheumatology
- PPARs and Anticancer Therapies
- (2010) Michael E. C. Robbins et al. PPAR Research
- PPARs in Human Neuroepithelial Tumors: PPAR Ligands as Anticancer Therapies for the Most Common Human Neuroepithelial Tumors
- (2010) Elisabetta Benedetti et al. PPAR Research
- Peroxisome Proliferator-Activated Receptor (PPAR)β /δ: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome
- (2010) Teresa Coll et al. Current Molecular Pharmacology
- Characterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components
- (2009) Matthias Goebel et al. ChemMedChem
- PPARs: the vasculature, inflammation and hypertension
- (2009) Sheng Zhong Duan et al. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
- HMGB1 Is Phosphorylated by Classical Protein Kinase C and Is Secreted by a Calcium-Dependent Mechanism
- (2009) Y. J. Oh et al. JOURNAL OF IMMUNOLOGY
- Non-histone nuclear factor HMGB1 is phosphorylated and secreted in colon cancers
- (2009) Hyun Ju Kang et al. LABORATORY INVESTIGATION
- Cerebroprotective action of telmisartan by inhibition of macrophages/microglia expressing HMGB1 via a peroxisome proliferator-activated receptor γ-dependent mechanism
- (2009) Tamami Haraguchi et al. NEUROSCIENCE LETTERS
- Peroxisome Proliferator-Activated Receptor-γ–Mediated Effects in the Vasculature
- (2008) Sheng Zhong Duan et al. CIRCULATION RESEARCH
- NF-κB and cancer—identifying targets and mechanisms
- (2008) Willscott E Naugler et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- The many faces of PPARγ: Anti-inflammatory by any means?
- (2008) Attila Szanto et al. IMMUNOBIOLOGY
- RAR/RXR and PPAR/RXR signaling in neurological and psychiatric diseases
- (2008) Sabien van Neerven et al. PROGRESS IN NEUROBIOLOGY
- Reduction in the Recurrence of Stroke by Eicosapentaenoic Acid for Hypercholesterolemic Patients
- (2008) Kortaro Tanaka et al. STROKE
- Microglia and Astrocyte Activation by Toll-Like Receptor Ligands: Modulation by PPAR-γAgonists
- (2008) Catherine Gurley et al. PPAR Research
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started